Vanderbilt, Bristol-Myers Squibb partner to advance Parkinson’s disease treatment

Vanderbilt University and Bristol-Myers Squibb Company announced today that they have signed a collaboration agreement for the discovery, development and commercialization of novel therapies acting on the mGluR4 glutamate receptor, known as positive allosteric modulators or PAMs, for the treatment of Parkinson’s disease.

Read the article:
Vanderbilt, Bristol-Myers Squibb partner to advance Parkinson’s disease treatment

Share and Enjoy:
  • Print
  • Digg
  • StumbleUpon
  • Facebook
  • Yahoo! Buzz
  • Twitter
  • Google Bookmarks
  • Add to favorites
  • email
  • LinkedIn
  • RSS
  • Tumblr
Share